Immediate Impact
1 from Science/Nature 55 standout
Citing Papers
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Epigenetics-targeted drugs: current paradigms and future challenges
2024 Standout
Works of Yuichi Tambo being referenced
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy
2017
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Yuichi Tambo | 361 | 305 | 99 | 41 | 460 | |
| Vega Iranzo | 191 | 280 | 104 | 43 | 437 | |
| Jumpei Kashima | 294 | 219 | 75 | 40 | 537 | |
| Ryo Ko | 378 | 290 | 121 | 58 | 528 | |
| Ester Del Signore | 292 | 390 | 106 | 43 | 539 | |
| Ryo Ariyasu | 257 | 264 | 80 | 49 | 424 | |
| Tamjeed Ahmed | 276 | 296 | 121 | 31 | 526 | |
| Anne Winther‐Larsen | 221 | 174 | 112 | 39 | 482 | |
| Jianjie Li | 225 | 235 | 121 | 42 | 499 | |
| Noelia Vilariño | 303 | 396 | 96 | 27 | 559 | |
| Masafumi Takeshita | 257 | 286 | 205 | 30 | 528 |
All Works
Login with ORCID to disown or claim papers
Loading papers...